With the official opening in February 2025 of a new viral vector production facility (VIFA One) in Mengeš, Slovenia, Novartis has strengthened its presence in that country. The company invested €40 million (US$43 million) into the facility, marking its first specialized viral vector manufacturing facility in Europe. Source: Biopharm International 28//3/2025